# OnCo record hera-b31-n9831 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/hera-b31-n9831/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "hera-b31-n9831", "NCT00045032" ;
  schema:name "HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)"@en ;
  schema:description "Three trials reported together in 2005 showed that a year of trastuzumab after surgery cuts the risk of dying from HER2-positive breast cancer by about a third."@en ;
  schema:url <https://onco.cc/trials/hera-b31-n9831/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00045032> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2001-11" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/nsabp-foundation/> ;
  onco:people <https://onco.cc/people/barbara-bradfield/>, <https://onco.cc/people/norman-wolmark/>, <https://onco.cc/people/charles-geyer/>, <https://onco.cc/people/david-cameron/>, <https://onco.cc/people/martine-piccart/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/>, <https://onco.cc/key-papers/paper-hera-b31-n9831-lancet-2017-update/> .